MU fight continues

In the health IT headlines this week was yet another effort to refocus the Meaningful Use program.

Led by the American Medical Association, a coalition of 111 medical societies sent letters for congressional leaders urging them to intervene on Stage 3. The coalition said that Stage 2 has "largely been a failure, with only 12 percent of physicians successfully participating and little improvement in data exchange across care settings."

The coalition asked Congress to refocus MU to achieve a "truly interoperable system of EHRs that will support, rather than hinder, the delivery of high quality care."

MU success "hinges on a laser-like focus on promoting interoperability and allowing innovation to flourish as vendors respond to the demands of physicians and hospitals rather than the current system where vendors must meet the ill-informed check-the-box requirements of the current program," the coalition wrote. 

Also this week was our coverage from the 2015 Connected Health Symposium, where the speakers touched on big data, cybersecurity, patient engagement and more.

Joichi Ito, director of the MIT Media Lab, said the traditional peer-reviewed, disciplinary, federally-funded research model is too narrow “considering the things we need to bring to bear. Research universities and large companies are ill-equipped to bring in the talent and thinking needed. Many different disciplines are involved in healthcare today, but the industry isn’t well designed to take advantage of all the technology, Ito said.

These different disciplines have evolved, but slowly. Funding also has been slow to keep up, he said. "Funding fails to cover the spaces between disciplines which are really rich with potential. This raises questions about how we do science."

When asked about the future of connected health, Ito said “the potential of technology is tremendous but won’t be deployed unless we fix some of the broken incentive models.” He talked about how there is incentive to deliver fixes but not necessarily to eliminate problems. However, "we’re understanding the human body in fundamentally new ways, especially in personalized medicine. All of technology should be fully integrated with medicine.”

Beth Walsh

Clinical Innovation + Technology editor

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup